Previous 10 | Next 10 |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundbe...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg, M.D., ...
Merus ([[MRUS]] +1.3%) prices an underwritten public offering of 4.85M common shares at a public offering price of $24.75 per share.Gross proceeds expected to be ~$120M.Offering is expected to close on or about January 25, 2021.Company intends to use the net proceeds to advance the clinical d...
Merus N.V. (NASDAQ:MRUS) intends to offer and sell up to $60M of shares of its common stock in an underwritten public offering.Underwriters have a 30-day option to purchase up to an additional $9M worth of stock.The company intends to use the net proceeds from this offering to advance the cli...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® ...
Eli Lilly's (LLY) R&D group Loxo Oncology (LOXO) and Merus (MRUS) announce a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics platform along with the scientific and rational drug design expertise of Loxo Oncology (LOXO) at Lilly t...
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies PR Newswire INDIANAPOLIS and UTRECHT, The Netherlands , Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Li...
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced collaborations w...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...
Gainers: Chimerix (CMRX) +59%. Jaguar Health (JAGX) +36%. Medigus (MDGS) +23%. Merus (MRUS) +22%. SCWorx (WORX) +20%.Losers: Sarepta Therapeutics (SRPT) -50%. SOS (SOS) -42%. Neoleukin Therapeutics (NLTX) -15%. Bionano Genomics (BNGO) -14%. Solid Biosciences (SLDB) -12%. For furth...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...